Clinical Trial Update: The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Diabetic Nephropathy [Phase 3]

View source ↗

Summary

A Phase 3 study assessing sitagliptin added to therapy with closed-loop control in adolescents with Type 1 diabetic nephropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetic Nephropathy

Drugs mentioned

• Sitagliptin (sitagliptin)

Snippet

Sponsor: Ain Shams University | Conditions: Type 1 Diabetic Nephropathy | Phase 3 | Status: COMPLETED